BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 32296584)

  • 1. Epithelial-mesenchymal transition status of circulating tumor cells in breast cancer and its clinical relevance.
    Zhou J; Zhu X; Wu S; Guo J; Zhang K; Xu C; Chen H; Jin Y; Sun Y; Zheng S; Chen Y
    Cancer Biol Med; 2020 Feb; 17(1):169-180. PubMed ID: 32296584
    [No Abstract]   [Full Text] [Related]  

  • 2. The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer.
    Guan X; Ma F; Li C; Wu S; Hu S; Huang J; Sun X; Wang J; Luo Y; Cai R; Fan Y; Li Q; Chen S; Zhang P; Li Q; Xu B
    Cancer Commun (Lond); 2019 Jan; 39(1):1. PubMed ID: 30606259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of the hormone receptor status of circulating tumor cell subpopulations based on epithelial-mesenchymal transition: a proof-of-principle study on the heterogeneity of circulating tumor cells.
    Guan X; Ma F; Liu S; Wu S; Xiao R; Yuan L; Sun X; Yi Z; Yang H; Xu B
    Oncotarget; 2016 Oct; 7(40):65993-66002. PubMed ID: 27602758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition.
    Gorges TM; Tinhofer I; Drosch M; Röse L; Zollner TM; Krahn T; von Ahsen O
    BMC Cancer; 2012 May; 12():178. PubMed ID: 22591372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epithelial-mesenchymal transition and stemness features in circulating tumor cells from breast cancer patients.
    Raimondi C; Gradilone A; Naso G; Vincenzi B; Petracca A; Nicolazzo C; Palazzo A; Saltarelli R; Spremberg F; Cortesi E; Gazzaniga P
    Breast Cancer Res Treat; 2011 Nov; 130(2):449-55. PubMed ID: 21298334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epithelial-mesenchymal transition and stem cell markers in patients with HER2-positive metastatic breast cancer.
    Giordano A; Gao H; Anfossi S; Cohen E; Mego M; Lee BN; Tin S; De Laurentiis M; Parker CA; Alvarez RH; Valero V; Ueno NT; De Placido S; Mani SA; Esteva FJ; Cristofanilli M; Reuben JM
    Mol Cancer Ther; 2012 Nov; 11(11):2526-34. PubMed ID: 22973057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High Expression of BCAR1 by Circulating Tumor Cells and Tumor Tissues Is Predictive of a Poor Prognosis of Early-Stage Lung Adenocarcinoma Potentially Due to Regulation of Epithelial-Mesenchymal Transition.
    Jiang S; Mao C; Jiang B; Tan Q; Deng B
    Technol Cancer Res Treat; 2020; 19():1533033820983086. PubMed ID: 33334252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epithelial-to-mesenchymal transition leads to disease-stage differences in circulating tumor cell detection and metastasis in pre-clinical models of prostate cancer.
    Lowes LE; Goodale D; Xia Y; Postenka C; Piaseczny MM; Paczkowski F; Allan AL
    Oncotarget; 2016 Nov; 7(46):76125-76139. PubMed ID: 27764810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients.
    Kallergi G; Papadaki MA; Politaki E; Mavroudis D; Georgoulias V; Agelaki S
    Breast Cancer Res; 2011 Jun; 13(3):R59. PubMed ID: 21663619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transcripts of circulating tumor cells detected by a breast cancer-specific platform correlate with clinical stage in bladder cancer patients.
    Todenhöfer T; Hennenlotter J; Dorner N; Kühs U; Aufderklamm S; Rausch S; Bier S; Mischinger J; Schellbach D; Hauch S; Feniuk N; Bedke J; Gakis G; Stenzl A; Schwentner C
    J Cancer Res Clin Oncol; 2016 May; 142(5):1013-20. PubMed ID: 26910601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Classification of circulating tumor cells by epithelial-mesenchymal transition markers.
    Wu S; Liu S; Liu Z; Huang J; Pu X; Li J; Yang D; Deng H; Yang N; Xu J
    PLoS One; 2015; 10(4):e0123976. PubMed ID: 25909322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status.
    Fehm T; Becker S; Duerr-Stoerzer S; Sotlar K; Mueller V; Wallwiener D; Lane N; Solomayer E; Uhr J
    Breast Cancer Res; 2007; 9(5):R74. PubMed ID: 17963511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EpCAM-independent isolation of circulating tumor cells with epithelial-to-mesenchymal transition and cancer stem cell phenotypes using ApoStream® in patients with breast cancer treated with primary systemic therapy.
    Le Du F; Fujii T; Kida K; Davis DW; Park M; Liu DD; Wu W; Chavez-MacGregor M; Barcenas CH; Valero V; Tripathy D; Reuben JM; Ueno NT
    PLoS One; 2020; 15(3):e0229903. PubMed ID: 32214335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular detection of epithelial-mesenchymal transition markers in circulating tumor cells from pancreatic cancer patients: Potential role in clinical practice.
    Zhao XH; Wang ZR; Chen CL; Di L; Bi ZF; Li ZH; Liu YM
    World J Gastroenterol; 2019 Jan; 25(1):138-150. PubMed ID: 30643364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epithelial-mesenchymal transition phenotypes of circulating tumor cells correlate with the clinical stages and cancer metastasis in hepatocellular carcinoma patients.
    Chen J; Cao SW; Cai Z; Zheng L; Wang Q
    Cancer Biomark; 2017 Dec; 20(4):487-498. PubMed ID: 28869439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating tumour cell-derived plastin3 is a novel marker for predicting long-term prognosis in patients with breast cancer.
    Ueo H; Sugimachi K; Gorges TM; Bartkowiak K; Yokobori T; Müller V; Shinden Y; Ueda M; Ueo H; Mori M; Kuwano H; Maehara Y; Ohno S; Pantel K; Mimori K
    Br J Cancer; 2015 Apr; 112(9):1519-26. PubMed ID: 25880010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of circulating tumour cell and the epithelial mesenchymal transition (EMT) status during eribulin-based treatment in 22 patients with metastatic breast cancer: a pilot study.
    Horimoto Y; Tokuda E; Murakami F; Uomori T; Himuro T; Nakai K; Orihata G; Iijima K; Togo S; Shimizu H; Saito M
    J Transl Med; 2018 Oct; 16(1):287. PubMed ID: 30342534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epithelial-to-mesenchymal Transition Heterogeneity of Circulating Tumor Cells and Their Correlation With MDSCs and Tregs in HER2-negative Metastatic Breast Cancer Patients.
    Papadaki MA; Aggouraki D; Vetsika EK; Xenidis N; Kallergi G; Kotsakis A; Georgoulias V
    Anticancer Res; 2021 Feb; 41(2):661-670. PubMed ID: 33517270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic classification of circulating tumor cells as a biomarker for metastasis and prognosis in breast cancer.
    Chen J; Ye C; Dong J; Cao S; Hu Y; Situ B; Xi X; Qin S; Xu J; Cai Z; Zheng L; Wang Q
    J Transl Med; 2020 Feb; 18(1):59. PubMed ID: 32028979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between circulating tumor cells and epithelial to mesenchymal transition in early breast cancer.
    Mego M; Cierna Z; Janega P; Karaba M; Minarik G; Benca J; Sedlácková T; Sieberova G; Gronesova P; Manasova D; Pindak D; Sufliarsky J; Danihel L; Reuben JM; Mardiak J
    BMC Cancer; 2015 Jul; 15():533. PubMed ID: 26194471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.